{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:55:56Z","timestamp":1788742556173,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100016083","name":"Hebei Provincial Department of Human Resources and Social Security","doi-asserted-by":"publisher","award":["B2024005038"],"award-info":[{"award-number":["B2024005038"]}],"id":[{"id":"10.13039\/100016083","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["molpharm.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Pharmacology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.molpha.2025.100065","type":"journal-article","created":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T06:28:10Z","timestamp":1753511290000},"page":"100065","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["The peroxisome proliferator\u2013activated receptor \u03b1\/\u03b2\/\u03b3 agonist NCPC-626 from microbial metabolites alleviates metabolic dysfunction\u2013associated steatohepatitis in mice"],"prefix":"10.1016","volume":"107","author":[{"given":"Man","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruolan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baohua","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingtong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuexia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhua","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.molpha.2025.100065_bib1","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease \u2013 a global public health perspective","volume":"70","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.molpha.2025.100065_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.molpha.2025.100065_bib3","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/hep4.1801","article-title":"Role of cholesterol-associated steatohepatitis in the development of NASH","volume":"6","author":"Horn","year":"2022","journal-title":"Hepatol Commun"},{"issue":"3","key":"10.1016\/j.molpha.2025.100065_bib4","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41591-023-02242-6","article-title":"Challenges and opportunities in NASH drug development","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.molpha.2025.100065_bib5","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of PPAR\u03b1 action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.molpha.2025.100065_bib6","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.3390\/ijms19071893","article-title":"Insights into the role of PPAR\u03b2\/\u03b4 in NAFLD","volume":"19","author":"Chen","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.molpha.2025.100065_bib7","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.semcdb.2012.01.003","article-title":"PPARs: fatty acid sensors controlling metabolism","volume":"23","author":"Poulsen","year":"2012","journal-title":"Semin Cell Dev Biol"},{"issue":"1","key":"10.1016\/j.molpha.2025.100065_bib8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3390\/cells9010037","article-title":"Anti-NASH drug development hitches a lift on PPAR agonism","volume":"9","author":"Boeckmans","year":"2019","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.molpha.2025.100065_bib9","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3390\/ijms19030913","article-title":"PPAR\u03b2\/\u03b4: a key therapeutic target in metabolic disorders","volume":"19","author":"Palomer","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.molpha.2025.100065_bib10","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.bbalip.2007.03.006","article-title":"PPAR\u03b3 in human and mouse physiology","volume":"1771","author":"Heikkinen","year":"2007","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"10.1016\/j.molpha.2025.100065_bib11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.phrs.2004.07.012","article-title":"An overview on biological mechanisms of PPARs","volume":"51","author":"Kota","year":"2005","journal-title":"Pharmacol Res"},{"issue":"15","key":"10.1016\/j.molpha.2025.100065_bib12","doi-asserted-by":"crossref","first-page":"8298","DOI":"10.3390\/ijms22158298","article-title":"PPARs as metabolic sensors and therapeutic targets in liver diseases","volume":"22","author":"Monroy-Ramirez","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.molpha.2025.100065_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.136","article-title":"Saroglitazar, a novel PPAR\u03b1\/\u03b3 agonist with predominant PPAR\u03b1 activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models","volume":"3","author":"Jain","year":"2015","journal-title":"Pharmacol Res Perspect"},{"issue":"4","key":"10.1016\/j.molpha.2025.100065_bib14","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"issue":"17","key":"10.1016\/j.molpha.2025.100065_bib15","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.molpha.2025.100065_bib16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40265-021-01648-1","article-title":"Chiglitazar: first approval","volume":"82","author":"Deeks","year":"2022","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.molpha.2025.100065_bib17","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/cbdd.14020","article-title":"A new insight into the treatment of diabetes by means of pan PPAR agonists","volume":"100","author":"Chandra","year":"2022","journal-title":"Chem Biol Drug Des"},{"issue":"14","key":"10.1016\/j.molpha.2025.100065_bib18","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.molpha.2025.100065_bib19","first-page":"465","article-title":"A cell-based high-throughput screening assay for farnesoid X receptor agonists","volume":"20","author":"Zheng","year":"2007","journal-title":"Biomed Environ Sci"},{"issue":"4","key":"10.1016\/j.molpha.2025.100065_bib20","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1124\/mol.117.108829","article-title":"Altenusin, a nonsteroidal microbial metabolite, attenuates nonalcoholic fatty liver disease by activating the farnesoid X receptor","volume":"92","author":"Zheng","year":"2017","journal-title":"Mol Pharmacol"},{"issue":"6","key":"10.1016\/j.molpha.2025.100065_bib21","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.molpha.2025.100065_bib22","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s10565-020-09544-2","article-title":"Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists","volume":"37","author":"Boeckmans","year":"2021","journal-title":"Cell Biol Toxicol"},{"issue":"5","key":"10.1016\/j.molpha.2025.100065_bib23","doi-asserted-by":"crossref","first-page":"G1035","DOI":"10.1152\/ajpgi.00199.2004","article-title":"Obese and diabetic db\/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin","volume":"287","author":"Sahai","year":"2004","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.molpha.2025.100065_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118457","article-title":"Liraglutide modulates gut microbiome and attenuates nonalcoholic fatty liver in db\/db mice","volume":"261","author":"Liu","year":"2020","journal-title":"Life Sci"},{"key":"10.1016\/j.molpha.2025.100065_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.934136","article-title":"Dapagliflozin protects against nonalcoholic steatohepatitis in db\/db mice","volume":"13","author":"Qiao","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.molpha.2025.100065_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2023.101231","article-title":"Liver fibrosis in NAFLD\/NASH: from pathophysiology towards diagnostic and therapeutic strategies","volume":"95","author":"Parola","year":"2024","journal-title":"Mol Aspects Med"},{"issue":"12","key":"10.1016\/j.molpha.2025.100065_bib27","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.3390\/cells12121572","article-title":"Recent insights into the role of PPARs in disease","volume":"12","author":"Wagner","year":"2023","journal-title":"Cells"},{"issue":"20","key":"10.1016\/j.molpha.2025.100065_bib28","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.3390\/ijms20205055","article-title":"Exploration and development of PPAR modulators in health and disease: an update of clinical evidence","volume":"20","author":"Cheng","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.molpha.2025.100065_bib29","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nrendo.2016.135","article-title":"PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD","volume":"13","author":"Gross","year":"2017","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"10.1016\/j.molpha.2025.100065_bib30","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/HEP.0000000000000395","article-title":"Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study","volume":"78","author":"Hirschfield","year":"2023","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.molpha.2025.100065_bib31","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.3390\/biom13081264","article-title":"Current clinical trial status and future prospects of PPAR-targeted drugs for treating nonalcoholic fatty liver disease","volume":"13","author":"Kamata","year":"2023","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.molpha.2025.100065_bib32","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41575-020-00366-5","article-title":"Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors","volume":"18","author":"Francque","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.molpha.2025.100065_bib33","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/liv.14370","article-title":"Succinate-GPR-91 receptor signalling is responsible for nonalcoholic steatohepatitis-associated fibrosis: effects of DHA supplementation","volume":"40","author":"Liu","year":"2020","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.molpha.2025.100065_bib34","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.intimp.2014.09.009","article-title":"The role of nitrated fatty acids and peroxisome proliferator-activated receptor gamma in modulating inflammation","volume":"23","author":"Narala","year":"2014","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"10.1016\/j.molpha.2025.100065_bib35","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/hr.2013.157","article-title":"Telmisartan activates endogenous peroxisome proliferator-activated receptor-\u03b4 and may have anti-fibrotic effects in human mesangial cells","volume":"37","author":"Mikami","year":"2014","journal-title":"Hypertens Res"},{"issue":"4","key":"10.1016\/j.molpha.2025.100065_bib36","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","article-title":"A global view of the interplay between non-alcoholic fatty liver disease and diabetes","volume":"10","author":"Stefan","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.molpha.2025.100065_bib37","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jhep.2011.08.025","article-title":"The interaction of hepatic lipid and glucose metabolism in liver diseases","volume":"56","author":"Bechmann","year":"2012","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.molpha.2025.100065_bib38","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jhep.2017.10.031","article-title":"Preclinical models of non-alcoholic fatty liver disease","volume":"68","author":"Santhekadur","year":"2018","journal-title":"J Hepatol"},{"issue":"Suppl 8A","key":"10.1016\/j.molpha.2025.100065_bib39","doi-asserted-by":"crossref","first-page":"42S","DOI":"10.1016\/j.amjmed.2003.09.005","article-title":"Effect of thiazolidinediones on body weight in patients with diabetes mellitus","volume":"115","author":"Fonseca","year":"2003","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.molpha.2025.100065_bib40","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2337\/diacare.27.1.256","article-title":"Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association","volume":"27","author":"Nesto","year":"2004","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.molpha.2025.100065_bib41","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0092-8674(03)00269-1","article-title":"Peroxisome-proliferator-activated receptor \u03b4 activates fat metabolism to prevent obesity","volume":"113","author":"Wang","year":"2003","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.molpha.2025.100065_bib42","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/sj.bjp.0706745","article-title":"The PPAR\u03b1\/\u03b3 dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats","volume":"148","author":"Li","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.molpha.2025.100065_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.101958","article-title":"A novel fatty acid mimetic with pan-PPAR partial agonist activity inhibits diet-induced obesity and metabolic dysfunction-associated steatotic liver disease","volume":"85","author":"Sahin","year":"2024","journal-title":"Mol Metab"},{"issue":"12","key":"10.1016\/j.molpha.2025.100065_bib44","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1038\/s42255-022-00700-y","article-title":"A researcher's guide to preclinical mouse NASH models","volume":"4","author":"Gallage","year":"2022","journal-title":"Nat Metab"},{"issue":"5","key":"10.1016\/j.molpha.2025.100065_bib45","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/cts.13235","article-title":"Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH","volume":"15","author":"M\u00f8llerh\u00f8j","year":"2022","journal-title":"Clin Transl Sci"},{"issue":"6","key":"10.1016\/j.molpha.2025.100065_bib46","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/hep4.1057","article-title":"The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis","volume":"1","author":"Wettstein","year":"2017","journal-title":"Hepatol Commun"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X2515325X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X2515325X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T12:35:19Z","timestamp":1772800519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026895X2515325X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0026895X2515325X"],"URL":"https:\/\/doi.org\/10.1016\/j.molpha.2025.100065","relation":{},"ISSN":["0026-895X"],"issn-type":[{"value":"0026-895X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The peroxisome proliferator\u2013activated receptor \u03b1\/\u03b2\/\u03b3 agonist NCPC-626 from microbial metabolites alleviates metabolic dysfunction\u2013associated steatohepatitis in mice","name":"articletitle","label":"Article Title"},{"value":"Molecular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molpha.2025.100065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100065"}}